Table 1.
Baseline characteristics of the study population.
| NLR | p | PLR | p | LMR | p | SII | p | |||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| <2.34 | ≥2.34 | <142.00 | ≥142.00 | <4.00 | ≥4.00 | <460.66 | ≥460.66 | |||||
| n(%) | n(%) | n(%) | n(%) | n(%) | n(%) | n (%) | n (%) | |||||
| Median age, years (range) | 58(33–86) | 56(27–77) | 0.737 | 62(33–86) | 51(35–70) | 0.243 | 50(33–73) | 61(33–83) | 0.258 | 58(33–86) | 56(27–77) | 0.422 |
| Gender | ||||||||||||
| Male | 29(61.7) | 29(60.4) | 0.898 | 30(62.5) | 28(59.6) | 0.770 | 28(58.3) | 30(63.8) | 0.583 | 33(68.8) | 25(53.2) | 0.144 |
| Female | 18(38.3) | 19(39.6) | 18(37.5) | 19(40.4) | 20(41.7) | 17(36.2) | 15(31.3) | 22(46.8) | ||||
| ECOG performance status | ||||||||||||
| 0 | 30(63.8) | 25(52.1) | 0.246 | 29(60.4) | 26(55.3) | 0.615 | 27(56.3) | 28(59.6) | 0.743 | 29(60.4) | 26(55.3) | 0.680 |
| 1 | 17(36.2) | 23(47.9) | 19(39.6) | 21(44.7) | 21(43.8) | 19(40.4) | 19(39.6) | 21(44.7) | ||||
| Tumor localization | ||||||||||||
| Left colon | 14(29.8) | 16(33.3) | 0.132 | 17(35.4) | 13(27.7) | 0.392 | 14(29.2) | 16(34.0) | 478 | 14(29.2) | 16(34.0) | 0.098 |
| Right colon | 3(6.4) | 9(18.8) | 4(8.3) | 8(17.0) | 8(16.7) | 4(8.5) | 3(6.3) | 9(19.1) | ||||
| Rectum | 30(63.8) | 23(47.9) | 27(56.3) | 26(55.3) | 26(54.2) | 27(57.4) | 31(64.6) | 22(46.8) | ||||
| Liver metastasis | ||||||||||||
| Yes | 35(74.5) | 36(75.0) | 0.952 | 37(77.1) | 34(72.3) | 0.595 | 35(72.9) | 36(76.6) | 0.680 | 36(75.0) | 35(74.5) | 1.000 |
| No | 12(25.5) | 12(25.0) | 11(22.9) | 13(27.7) | 13(27.1) | 11(23.4) | 12(25.0) | 12(25.5) | ||||
| Lung metastasis | ||||||||||||
| Yes | 23(48.9) | 20(41.7) | 0.477 | 24(50.0) | 19(40.4) | 0.349 | 21(43.8) | 22(46.8) | 0.765 | 24(50.0) | 19(40.4) | 0.412 |
| No | 24(51.1) | 28(58.3) | 24(50.0) | 28(59.6) | 27(56.3) | 25(53.2) | 24(50.0) | 28(59.6) | ||||
| Pathological differentiation | ||||||||||||
| Low | 13(27.7) | 20(41.7) | 0.144 | 15(31.3) | 18(38.3) | 0.360 | 16(33.3) | 17(36.2) | 0.866 | 15(31.3) | 18(38.3) | 0.360 |
| Median | 30(63.8) | 21(43.8) | 29(60.4) | 22(46.8) | 27(56.3) | 24(51.1) | 29(60.4) | 22(46.8) | ||||
| High | 4(8.5) | 7(14.6) | 4(8.3) | 7(14.9) | 5(10.4) | 6(12.8) | 4(8.3) | 7(14.9) | ||||
| M stage | ||||||||||||
| M1a | 17(36.2) | 22(45.8) | 0.338 | 18(37.5) | 21(44.7) | 0.477 | 21(43.8) | 18(38.3) | 0.589 | 17(35.4) | 22(46.8) | 0.301 |
| M1b | 30(63.8) | 26(54.2) | 30(62.5) | 26(55.3) | 27(56.3) | 29(61.7) | 31(64.6) | 25(53.2) | ||||
| CT regimen | ||||||||||||
| FOLFOX | 15(31.9) | 11(22.9) | 0.325 | 12(25.0) | 14(29.8) | 0.601 | 13(27.1) | 13(27.7) | 0.950 | 15(31.3) | 11(23.4) | 0.491 |
| FOLFIRI | 32(68.1) | 37(77.1) | 36(75.0) | 33(70.2) | 35(72.9) | 34(72.3) | 33(68.8) | 36(76.6) | ||||
Abbreviations: NLR, neutrophil-to-lymphocyte ratio; PLR, platelet-to-lymphocyte ratio; LMR, lymphocyte-to-monocyte ratio; SII, systemic immune-inflammation index; ECOG, Eastern Cooperative Oncology Group; n, number.
A p value < 0.05 was considered statistically significant.